Richard Greil

1989–2026 年に発表

274
論文数
38,814
被引用数
104
h 指数
257
i10 指数

被引用数

Richard Greil の年別被引用数1948 年: 被引用 1 件1990 年: 被引用 3 件1991 年: 被引用 1 件1992 年: 被引用 1 件1993 年: 被引用 5 件1995 年: 被引用 1 件1996 年: 被引用 1 件1997 年: 被引用 2 件1998 年: 被引用 13 件1999 年: 被引用 7 件2000 年: 被引用 12 件2001 年: 被引用 21 件2002 年: 被引用 33 件2003 年: 被引用 30 件2004 年: 被引用 26 件2005 年: 被引用 40 件2006 年: 被引用 51 件2007 年: 被引用 64 件2008 年: 被引用 74 件2009 年: 被引用 101 件2010 年: 被引用 136 件2011 年: 被引用 184 件2012 年: 被引用 186 件2013 年: 被引用 243 件2014 年: 被引用 234 件2015 年: 被引用 275 件2016 年: 被引用 236 件2017 年: 被引用 254 件2018 年: 被引用 239 件2019 年: 被引用 863 件2020 年: 被引用 1,264 件2021 年: 被引用 1,348 件2022 年: 被引用 1,360 件2023 年: 被引用 1,126 件2024 年: 被引用 2,060 件2025 年: 被引用 1,065 件2026 年: 被引用 26 件1949〜1989 年は被引用が無いため表示していません1994 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,908 件、この内訳の 21.3%中国: 引用元論文 1,520 件、この内訳の 8.3%イタリア: 引用元論文 1,311 件、この内訳の 7.2%ドイツ: 引用元論文 1,219 件、この内訳の 6.6%イギリス: 引用元論文 1,094 件、この内訳の 6%フランス: 引用元論文 844 件、この内訳の 4.6%スペイン: 引用元論文 695 件、この内訳の 3.8%カナダ: 引用元論文 617 件、この内訳の 3.4%スイス: 引用元論文 582 件、この内訳の 3.2%オーストラリア: 引用元論文 530 件、この内訳の 2.9%日本: 引用元論文 524 件、この内訳の 2.9%オランダ: 引用元論文 455 件、この内訳の 2.5%
0%21.3%その他 27.3%

分野

  • Medicine71.2%
  • Biochemistry, Genetics and Molecular Biology21.3%
  • Immunology and Microbiology3.8%
  • Neuroscience0.5%
  • Agricultural and Biological Sciences0.5%
  • Engineering0.5%
  • その他2.2%

トピック

  • Cancer Immunotherapy and Biomarkers5.5%
  • Lymphoma Diagnosis and Treatment3.7%
  • Breast Cancer Treatment Studies3.3%
  • CAR-T cell therapy research3%
  • HER2/EGFR in Cancer Research2.7%
  • Chronic Lymphocytic Leukemia Research2.4%
  • その他79.4%

共著者

全論文

検索で開く
  1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bo Gao, Brett Hughes, Girish Mallesara, Danny Rischin, Anne L. Taylor, Martin Burian, Thorsten Fuereder, Richard Greil, Carlos H. Barrios, Dalvaro Oliveira de Castro Junior, Gilberto de Castro, Fábio Franke, Gustavo Girotto, Iane Pinto Figueiredo Lima, Ulisses Ribaldo Nicolau, Gustavo Dix Junqueira Pinto, Lucas Vieira dos Santos, Ana-Paula Victorino, Neil Chua, Félix Couture, Richard Gregg, Aaron R. Hansen, John Hilton, Joy McCarthy, Denis Soulières, Rodrigo Ascuí, Pablo Gonzalez, Luis J. Villanueva-Rivera, Marco Torregroza, Ángela R. Zambrano, Petra Holečková, Zdeněk Král, Bohuslav Melichar, Prausova Jana, Milan Vošmik, Maria Andersen, Niels Gyldenkerne, Hannes Jürgens, Kadri Putnik, Petri Reinikainen, Viktor Gruenwald, Simon Laban, Gerasimos Aravantinos, Ioannis Boukovinas, Vassilis Georgoulias, Amanda Psyrri, D.L.W. Kwong, Yousuf Al-Farhat, Tibor Csőszi, József Erfán, Geza Horvai, László Landherr, Éva Remenár, Ágnes Ruzsa, Judit Szota, Salem Billan, Iris Gluck, Orit Gutfeld, Aron Popovtzer, Marco Benasso, Simona Bui, Vittorio Ferrari, Lisa Licitra, Franco Nolè, Takashi Fujii, Yasushi Fujimoto, Nobuhiro Hanai, Hiroki Hara, Koji Matsumoto, Kenji Mitsugi ほか 119 名 - The Lancet 2019 被引用: 3,211

  2. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christopher R. Flowers, Gilles Salles - New England Journal of Medicine 2021 被引用: 843

  3. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 490

  4. Spatial predictors of immunotherapy response in triple-negative breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 被引用: 325

  5. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunil R. Lakhani, W Janni, Barbro Linderholm, T.-W. Liu, Niklas Loman, Larissa A. Korde, Sibylle Loibl, Peter C. Lucas, Frederik Marmé, E. Martinez de Dueñas, Robin McConnell, Kelly‐Anne Phillips, Martine Piccart, Giovanna Rossi, Rita K. Schmutzler, Elżbieta Senkus, Zhi-Ming Shao, Priyanka Sharma, Christian F. Singer, Tanja Španić, Elmar Stickeler, Masakazu Toi, Tiffany A. Traina, Giuseppe Viale, Gabriele Zoppoli, Y.H. Park, Rinat Yerushalmi, Huan Yang, D. Pang, Kyung Hae Jung, Audrey Mailliez, Zhaoqing Fan, Isabelle Tennevet, J. Zhang, T. Nagy, Gabe S. Sonke, Qiuhong Sun, Marina Parton, Marco Colleoni, Marcus Schmidt, Adam Brufsky, W. Razaq, Bella Kaufman, David Cameron, Christine Campbell, Andrew Tutt, P. Sevelda, Ferdinand Haslbauer, Monika Penzinger, Leopold Öhler, Christoph Tinchon, Richard Greil, Sonja Heibl, Rupert Bartsch, Viktor Wette, Christian F. Singer, Claudia Pasterk, Ruth Helfgott, Gunda Pristauz-Telsnigg, Herbert Stöger, A. Weltermann, Daniel Egle, I. Thiel, David Fuchs, Holger Rumpold, Kathrin Strasser‐Weippl, Beate Rautenberg, Volkmar Müller, Marcus Schmidt, Stefan Paepke ほか 509 名 - Annals of Oncology 2022 被引用: 447

  6. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 被引用: 520

  7. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

    著者: , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2022 被引用: 386

  8. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 518

  9. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Hillmen - The Lancet Oncology 2022 被引用: 278

  10. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Otto Metzger, Anita Jallitsch-Halper, Kadine Solomon, Céline Schurmans, K. P. Theall, Dongrui R. Lu, Kathleen Tenner, Christian Fesl, Angela DeMichele, Erica L. Mayer, on behalf of the PALLAS groups and investigators - Journal of Clinical Oncology 2021 被引用: 231

  11. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Evan Y. Yu - Journal of Clinical Oncology 2023 被引用: 132

  12. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Margaret McGrath, Richard Greil, Dietmar Thurnher, Thorsten Fuereder, Martin Burian, Sylvie Rottey, Jean‐Pascal Machiels, Paul Clement, Stéphanie Henry, S. Deheneffe, Gustavo Vasconcelos Alves, Iane Pinto Figueiredo Lima, Josiane Mourão Dias, Pedro Rafael Martins De Marchi, Milena Perez Mak, Andrea Juliana Gomes, Dalvaro Oliveira de Castro Junior, Tatiane Cardoso Motta, Mônica Luciana Agostinho Padoan, Ana Paula Victorina, Sérgio Jobim Azevedo, Lillian L. Siu, Stephanie Yasmin Brule, John Hilton, Chang Shu Wang, Nathaniel Bouganim, Marc Webster, John Walker, Neil Chua, Ángela R. Zambrano, Alicia Quiroga Echeverri, Oscar Mauricio Niño Gomez, Carlos Alberto Ortiz, Luis Alejandro Rojas, Andrés Cardona Zorilla, Olga Marcela Urrego Meléndez, Petra Holečková, Bohuslav Melichar, Jakub Cvek, Jana Prausová, Milan Vošmik, Jean‐Pierre Delord, Xavier Zasadny, Lionnel Geoffrois, Yungan Tao, Y. Pointreau, Rainer Fietkau, Marlen Haderlein, Andreas Müller, Ursula C. Schroeder, Barbara Wollenberg, Simon Laban, Philipp Ivanyi, Viktor Gruenwald, Philippe Schafhausen, Orit Gutfeld, Iris Gluck, Aron Popovtzer, Amichay Meirovitz, Salem Billan, Baruch Brenner, Aron Popovtzer, Dror Limon, Lisa Licitra, Francesco Perri, Francesco Caponigro, Martina Violati, Daris Ferrari, Franco Nolè, Federica Bertolini ほか 90 名 - The Lancet Oncology 2024 被引用: 210

  13. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 207

  14. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

    著者: , , , , , , , , , , , , , , , , - The Lancet Oncology 2012 被引用: 1,164

  15. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ernst Forjan, Emanuil Gheorghita, Richard Greil, Antónia Hatalova, M Hrubisko, János Jakucs, Polina Kaplan, Sergiy Klymenko, Steffen Koschmieder, Mihaela Lazaroiu, Tamila Lysa, Zvenyslava Masliak, Tamás Masszi, Georgi Mihaylov, Alexander Myasnikov, Uwe Platzbecker, Mathieu Puyade, Jérôme Rey, Lydia Roy, Jiřı́ Schwarz, Aleksander B. Skotnicki, I. Ya. Sokolova, Maria Soroka‐Wojtaszko, Jolanta Starzak-Gwóźdź, Vera Stoeva, Jose Miguel Torregrosa‐Diaz, Anna Vallova, Elena Volodicheva, Krzysztof Warzocha, Ella Willenbacher, Dominik Wolf‎ - The Lancet Haematology 2020 被引用: 347

  16. Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: subgroup analysis by Programmed Death Ligand-1 combined positive score

    著者: , , , , , , , , , , , , , , , , , , , , - 2022 被引用: 177

  17. Adjuvant nab -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michele Reni, Richard A. Epstein, Paul L. Vasey, Jeremy Shapiro, Matthew Burge, Yu Jo Chua, Marion Harris, Nick Pavlakis, Niall C. Tebbutt, Gerald W. Prager, Christian Dittrich, Friedrich Längle, Kathrin Philipp‐Abbrederis, Richard Greil, Herbert Stöger, Michael Girschikofsky, Thomas Kuehr, Jean–Luc Van Laethem, Stéphanie Laurent, Neesha C. Dhani, Yoo Joung Ko, Scot Dowden, Petr Kavan, Mustapha Édouard Tehfe, Eugen Kubala, Milan Kohoutek, Per Pfeiffer, Mette Yilmaz, Vibeke K. Parner, Tapio Salminen, Leena‐Maija Soveri, Eija Korkeila, Pia Österlund, Julien Taı̈eb, David Tougeron, Pascal Artru, François‐Xavier Caroli‐Bosc, Rosine Guimbaud, Antony Turpin, Thomas Walter, Jean‐Baptiste Bachet, Volker Kunzmann, Florian Kreth, Andreas De Block, Marino Venerito, Helmut Oettle, Meinolf Karthaus, Jörg Trojan, Gunnar Folprecht, Markus M. Lerch, Frank Kullmann, Marcel Reiser, Volker Heinemann, Marcus‐Alexander Wörns, H. Schulz, Benjamin Garlipp, Thomas Yau, Lam Stephen Chan, Balázs Juhász, László Landherr, Tamás Pintér, G. Bodoky, Zsuzsanna Kahán, Raymond McDermott, Derek G. Power, Luca Gianni, Salvatore Siena, Michèle Milella, Alfredo Falcone, Rossana Berardi ほか 87 名 - Journal of Clinical Oncology 2022 被引用: 132

  18. Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martina Degiorgis, Silvia Khodaverdi, Richard Greil, Ásgerður Sverrisdóttir, Marta Paoli, Ethel Seyll, Sibylle Loibl, Barbro Linderholm, Gabriele Zoppoli, Nancy E. Davidson, Oskar T. Johannsson, Philippe L. Bédard, Sherene Loi, Susan Knox, David Cameron, Nadia Harbeck, Maite Lasa Montoya, Mariana Brandão, Andrea Vingiani, Carmela Caballero, Florentine Hilbers, Lucy Yates, Matteo Benelli, David Venet, Martine Piccart - Cancer Discovery 2021 被引用: 177

  19. CAR T-Cell Therapy in Hematological Malignancies

    著者: , , , - International Journal of Molecular Sciences 2021 被引用: 174

  20. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wim Demey, Paul Germonpré, Elke Govaerts, Thierry Pieters, Reinier Wener, Alan A. Azambuja, Giuliano Santos Borges, Gilberto de Castro, Suellen Castro, Felipe Melo Cruz, Fábio Franke, Eduardo Silva, Parneet Cheema, Robert H. El-Maraghi, Swati Kulkarni, Rami Nassabein, Scott Owen, Clarisse Audigier-Valette, Jaafar Bennouna, C. Chouaïd, Alexis B. Cortot, S. Couraud, D. Debieuvre, Fabrice Denis, Patrick Dumont, Radj Gervais, Nicolas Girard, Etienne Giroux‐Leprieur, Florian Guisier, Sandrine Hiret, Henri Janicot, Corinne Lamour, J. Madelaine, M. Marcq, E. Pluquet, Jean Louis Pujol, Magali Ravoire, Marielle Sabatini, A. Vergnenègre, Sabine Bohnet, Martin Faehling, Melanie Janning, Eckart Laack, Niels Reinmuth, Achim Rittmeyer, Claas Wesseler, Sofia Baka, George Fountzilas, Panagiotis Katsaounis, Αthanasios Kotsakis, Ioannis Mountzios, Konstantinos Syrigos, Julia Dudnik, Fink Carmel, Ofer Merimsky, Hovav Nechushtan, Julia Sobolev, Franceso Agustoni, Anna Bettini, Matteo Brighenti, Giulio Cerea, Filippo de Marinis, Salvatore Grisanti, Francesco Grossi, Andrea Luciani, Evaristo Maiello, Héctor Soto Parrà, Pierfrancesco Tassone, Giuseppe Tonini, Yoko Agemi ほか 101 名 - Journal of Clinical Oncology 2024 被引用: 115

  21. Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2023 被引用: 101

  22. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2018 被引用: 548

  23. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site

    著者: , , , , , , , - Journal of Hematology & Oncology 2016 被引用: 327

  24. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Blood 2020 被引用: 169